Chau KHY, et al. - Researchers sought to describe the patterns of uptake of bioresorbable vascular scaffolds (BVS) after US Food and Drug Administration (FDA) approval, as well as changes in response to subsequent releases of data and US FDA safety warnings for BVS. The CathPCI Registry was analyzed from January 2016 and June 2017, indicating the monthly use of BVS reaching a maximum of 1.25% of all stent procedures in the 90 days post–FDA approval. Following the release of new data and FDA warnings associated with BVS, they observed a sharp decline in use over the ensuing month. These findings suggest the selective nature of most interventional cardiologists and hospitals in using BVS after FDA approval and indicate their appropriate response to data that reported negative outcomes by curtailing use.